Preferencje help
Polish version English version Język
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 11

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

Wyszukiwano:
w słowach kluczowych:  retinoic acid
help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
1

Antagonizing retinoic acid receptors increases myeloid cell production by cultured human hematopoietic stem cells

100%
Brown G., Marchwicka A., Cunningham A., Toellner K.-M., Marcinkowska E.
Archivum Immunologiae et Therapiae Experimentalis
|
2017
|
tom 65
|
nr 1
2

Topical retinoic acid in the treatment of feline tail gland hyperplasia [stud.tail]: a prospective clinical trial

100%
Ural K., Acar A., Guzel M., Karakurum M. C., Cingi C. C.
Bulletin of the Veterinary Institute in Puławy
|
2008
|
tom 52
|
nr 3
The purpose of this prospective, double-blinded, and placebo-controlled clinical trial was to investigate the efficacy of topical cream, containing 0.1% retinoic acid for the treatment of tail gland hyperplasia in cats. Nineteen privately owned cats diagnosed with tail gland hyperplasia, based on history and clinical findings were randomly assigned to either a placebo or an active ingredient treatment group. Clinical evaluations were done by the same investigator, who scored clinical healing, at the beginning, during, and at the end of the treatment. Both owners and investigators were blinded to the allocation to the groups. It was demonstrated that retinoic acid gel treatment significantly decreased (P<0.05) the investigator's clinical scores while no significant changes were detected in the placebo treatment group. In conclusion, treatment with 0.1% retinoic acid cream was effective for the topical management of tail gland hyperplasia in the cats included in the study.
3

Cytokine action and oxidative stress response in differentiated neuroblastoma SH-SY5Y cells

100%
Kania J., Baranska A., Guzdek A.
Acta Biochimica Polonica
|
2003
|
tom 50
|
nr 3
In the retinoic acid-differentiated neuroblastoma SH-SY5Y cells, IL-1 induced bind­ing activity of NFkB and up-regulated the expression and activity of MnSOD. The IL-1-elicited effects were partly reversed by IL-4 and IL-6. It is proposed that IL-4 and IL-6 may participate in the regulation of the imbalanced oxidant status induced by IL-1 in differentiated neuroblastoma cells. In the SH-SY5Y cell line, TNFa neither ac­tivated NFkB nor induced MnSOD expression and activity, but was capable of modu­lating the IL-1 effects. Pyrrolidine dithiocarbamate (PDTC), an inhibitor of NFkB acti­vation, down-regulated the expression and activity of MnSOD, which may suggest that the regulation of MnSOD by IL-1 in retinoic acid-differentiated neuroblastoma cells was mediated by the nuclear factor kB.
4

Quantity examination of E6 and E7 proteins of HPV 18 in HeLa cell line incubated with retinoid acid

100%
Dziubinska-Parol I., Gasowska U., Rzymowska J., Wojcierowski J., Kwasniewska A.
Bulletin of the Veterinary Institute in Puławy. Supplement
|
2002
5

Celecoxib increases retinoid sensitivity in human colon cancer cell lines

84%
Liu J. P., Wei H.-B., Zheng Z.-H., Guo W.-P., Fang J.-F.
Cellular and Molecular Biology Letters
|
2010
|
tom 15
|
nr 3
440-450
Retinoid resistance has limited the clinical application of retinoids as differentiation-inducing and apoptosis-inducing drugs. This study was designed to investigate whether celecoxib, a selective COX-2 inhibitor, has effects on retinoid sensitivity in human colon cancer cell lines, and to determine the possible mechanism of said effects. Cell viability was measured using the MTT assay. Apoptosis was detected via Annexin-V/PI staining and the flow cytometry assay. PGE2 production was measured with the ELISA assay. The expression of RARβ was assayed via western blotting. The results showed that celecoxib enhanced the inhibitory effect of ATRA in both COX-2 high-expressing HT-29 and COX-2 low-expressing SW480 cell lines. Further study showed the ATRA and celecoxib combination induced greater apoptosis, but that the addition of PGE2 did not affect the enhanced growth-inhibitory and apoptosis-inducing effects of the combination. Moreover, NS398 (another selective COX-2 inhibitor) did not affect the inhibitory effects of ATRA in the two cell lines. Western blotting showed that the expression of RARβ in HT-29 cell lines was increased by celecoxib, but not by NS398, and that the addition of PGE2 did not affect the celecoxib-induced expression of the retinoic acid receptor beta. In conclusion, celecoxib increased the expression of RARβ and the level of cellular ATRA sensitivity through COX-2-independent mechanisms. This finding may provide a potential strategy for combination therapy.
6

Effect of 9-cis retinoic acid [RA] on progesterone and estradiol secretion and RA receptor expression in the chicken ovarian follicles

84%
Pawlowska K., Sechman A., Suchanek I., Grzegorzewska A., Rzasa J.
Folia Biologica
|
2008
|
tom 56
|
nr 1-2
65-72
7

5'-Esters of 2'-deoxyadenosine and 2-chloro-2'-deoxyadenosine with cell differentiation-provoking agents

84%
Grieb P., Kryczka T., Wojtowicz R., Kawiak J., Kazimierczuk Z.
Acta Biochimica Polonica
|
2002
|
tom 49
|
nr 1
Phenylacetic and retinoic acids are carboxyacidic cell differentiating agents display­ing anticancer activities. We report on a new class of compounds including the 5'-es- ters of 2'-deoxyadenosine (dA) or 2-chloro-2'-deoxyadenosine (cladribine, 2CdA) and the aforementioned acids. The rationale behind the synthesis of these esters was that if they are hydrolyzed inside the lymphoid cells, either dA will be removed from the intracellular environment by deamination, or 2CdA will be phosphorylated and accu­mulated. In either case targetted delivery of the differentiating agent to the lymphoid cells may be envisaged. The said compounds were synthesized by the Mitsunobu pro­cedure employing triphenylphosphine and azadicarboxylic acid esters, and their sta­bility was tested against various esterases. Esters of dA and 2CdA with phenylacetic acids were found to be resistant to enzymatic hydrolysis, whereas those with retinoic acids were efficiently hydrolyzed by commercially available hepatic esterase as well as by esterases present in the blood plasma and in diluted human lymphocyte lysate. Susceptibility to enzymatic hydrolysis was found to be a prerequisite of cytotoxic and/or differentiating activity of these esters in leukemic cell lines.
8
Content available remote

Short term 13-cis-retinoic acid treatment at therapeutic doses elevates expression of leptin, GLUT4, PPARgamma and aP2 in rat adipose tissue

67%
Krskova-Tybitanclova K., Macejova D., Brtko J., Baculikova M., Krizanova O., Zorad S.
Journal of Physiology and Pharmacology
|
2008
|
tom 59
|
nr 4
731-743
Temporary defects in the plasma lipid and glucose homeostasis are frequent complication accompanying chronic treatment with 13-cis-retinoic acid (13cRA). White adipose tissue acts as an endocrine organ producing a variety of hormones (adipocytokines) including leptin, adiponectin, tumor-necrosis factor alpha (TNF) and angiotensin II (Ang II), which influence lipid metabolism, systemic insulin sensitivity and inflammation. To study the effect of a short-term 13cRA administration on metabolism of epididymal fat tissue, we treated Wistar rats with five identical therapeutic doses of 13cRA (0.8 mg/kg b.w.) by gavage during a period of 10 days. Expression of adiponectin, leptin, TNF and selected proteins such as adipocyte fatty acid binding protein (aP2), insulin-dependent glucose transporter GLUT4, peroxisome proliferator-activated receptor gamma (PPAR) and retinoid X receptors (RXRs) was investigated using RT-PCR. Short-term treatment with therapeutic doses of 13cRA caused significant increase of the aP2, PPAR and moderately RXR gene expression. Similarly, the relative amount of mRNA for leptin and GLUT4 was increased, while the TNF transcript was decreased after treatment with 13cRA. The gene expression and plasma concentration of adiponectin were without any significant changes. Since local adipose renin-angiotensin system (RAS) has been presumed to be involved in the regulation of fat tissue metabolism, we also investigated the gene expression of RAS components in epididymal fat depot. Our data has shown that 13cRA elevated Ang II receptor type 1 (AT1 receptor) - at both, mRNA and protein level. Thus, our results demonstrate that short-term 13cRA treatment is inducing alterations in fat tissue metabolism in relation to stimulated adipogenesis.
9

Expression of cellular retinoic acid-binding protein I and II (CRABP I and II) in embryonic mouse hearts treated with retinoic acid

67%
Stachurska E., Loboda A., Niderla-Bielinska J., Szperl M., Juszynski M., Jozkowicz A., Dulak J., Ratajska A.
Acta Biochimica Polonica
|
2011
|
tom 58
|
nr 1
Cellular retinoic acid binding proteins are considered to be involved in retinoic acid (RA) signaling pathways. Our aim was to compare the expression and localization of cellular retinoic acid binding proteins I and II (CRABP I and II) in embryonic mouse hearts during normal development and after a single teratogenic dose of RA. Techniques such as real-time PCR, RT-PCR, Western blots and immunostaining were employed to examine hearts from embryos at 9-17 dpc. RA treatment at 8.5dpc affects production of CRABP I and II in the heart in the 48-h period. Changes in expression of mRNA for retinaldehyde dehydrogenase II (Raldh2), Crabp1 and Crabp2 genes also occur within the same time window (i.e. 10-11dpc) after RA treatment. In the embryonic control heart these proteins are localized in groups of cells within the outflow tract (OT), and the atrioventricular endocardial cushions. A gradient of labeling is observed with CRABP II but not for CRABP I along the myocardium of the looped heart at 11 dpc; this gradient is abolished in hearts treated with RA, whereas an increase of RALDH2 staining has been observed at 10 dpc in RA-treated hearts. Some populations of endocardial endothelial cells were intensively stained with anti-CRABP II whereas CRABP I was negative in these structures. These results suggest that CRABP I and II are independently regulated during heart development, playing different roles in RA signaling, essential for early remodeling of the heart tube and alignment of the great arteries to their respective ventricles.
10
Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik
Content available

Effect of quercetin on bone mineral status and markers of bone turnover in retinoic acid-induced osteoporosis

67%
Orsolic N., Jelec Z., Nemrava J., Balta V., Gregorovic G., Jelec D.
Polish Journal of Food and Nutrition Sciences
|
2018
|
tom 68
|
nr 2
Retinoic acid-induced osteoporosis (RBM) is one of the most common causes of secondary osteoporosis. This study tested the anti-osteoporetic effect of quercetin in RBM-induced bone loss model (RBM). After 14-day supplementation of 13cRA to induce RBM, rats were administered with quercetin (100 mg/kg) or alendronate (40 mg/kg). We analysed changes in body and uterine weight of animals, femoral geometric characteristics, calcium and phosphorus content, bone weight index, bone hystology, bone mineral density (BMD), markers of bone turnover, lipid peroxidation, glutathione levels and SOD, CAT activity of liver, kidney spleen, and ovary as well as biochemical and haematological variables. In comparison to the control RBM rats, the treatment with quercetin increased bone weight index, BMD, osteocalcin level, femoral geometric characteristics, calcium and phosphorus content in the 13cRA-induced bone loss model. Histological results showed its protective action through promotion of bone formation. According to the results, quercetin could be an effective substitution for alendronate in 13cRA-induced osteoporosis. Good therapeutic potential of quercetin on rat skeletal system is based partly on its antioxidant capacity and estrogenic activity.
11

Ontogeny and TCR diversity of regulatory Foxp31plus T cells

67%
Ignatowicz L.
Archivum Immunologiae et Therapiae Experimentalis
|
2011
|
tom 59
|
nr 5
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.